Migraine: World Market Spotlight 2018-2022 - 638.4 Million Prevalent Cases in Adults Aged 20 Years & Older is Forecast by 2025

Dublin, June 28, 2019 (GLOBE NEWSWIRE) -- The "Market Spotlight: Migraine" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Migraine market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• The author estimates that in 2016, there were 569.8 million prevalent cases of migraine in adults aged 20 years and older worldwide, and forecasts that number to increase to 638.4 million prevalent cases by 2025.
• Latin America and the Caribbean is estimated to have the highest disease prevalence (16.4%), while Northern America has the lowest prevalence (9.7%).
• The majority of approved drugs in the migraine space target serotonin 5-HT1 receptors or GABA receptors. These are commonly administered via the oral route, with a few select products being available in intranasal, intramuscular, intra dermal, intra articular, intravesical, rectal, sublingual, transmucosal, and subcutaneous formulations.
• Industry-sponsored drugs in active clinical development for migraine are spread evenly across Phase I to the NDA/BLA phase. Mid- and late-stage drugs in development for migraine focus on a wide variety of targets. Among these classes, the CGRP hold considerable promise owing to their specific targeting of migraine mechanisms, contrary to conventional treatments, and prophylactic efficacy. Approximately half of the drugs in mid- and late-stage development for migraine are administered via the oral route, with the remainder being intranasal, inhaled, subcutaneous, intravenous, transdermal, sublingual, transmucosal, and intramuscular formulations.
• High-impact upcoming events for drugs in the migraine space comprise topline Phase II and Phase III trial results, expected CHMP opinions, and FDA decisions on NDAs/BLAs.
• The overall likelihood of approval of a Phase I migraine asset is 15.7%, and the average probability a drug advances from Phase III is 91.7%. Drugs, on average, take 7.7 years from Phase I to approval, compared to 9.6 years in the overall neurology space.
• There were 27 licensing and asset acquisition deals during 2013-18. The largest deal was the $573.5m exclusive agreement between Bristol-Myers Squibb and Biohaven in 2016 to develop and commercialize rimegepant and BHV-3500, as well as for rights to other CGRP-related intellectual property.
• Botox's sales were the highest of any approved migraine drug during 2012-17. The distribution of clinical trials across Phase I-IV indicates that the majority of trials for migraine have been in the early and mid-phases of development, with 55% of trials in Phase I-II, and 45% in Phase III-IV.
• The US has a substantial lead in the number of migraine clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
• Clinical trial activity in the migraine space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for migraine, with 95 trials.
• GlaxoSmithKline leads the industry sponsors with by far the highest number of clinical trials for migraine, followed by Merck & Co and Eli Lilly.

Key Topics Covered

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND
Subtypes

TREATMENT
Analgesics
NSAIDs
Serotonergic drugs
Prophylactic agents for migraine

EPIDEMIOLOGY

MARKETED DRUGS
Approvals by country

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
Fremanezumabor for Migraine
Atogepant for Migraine
Emgality for Migraine
Ubrogepant for Migraine
Ubrogepant for Migraine
Eptinezumab for Migraine
Rimegepant for Migraine
Rimegepant for Migraine
Ubrogepant for Migraine
Aimovig for Migraine
Eptinezumab for Migraine
Emgality for Migraine
Lasmiditan for Migraine
Eptinezumab for Migraine
Fremanezumab for Migraine
Fremanezumab for Migraine
Emgality for Migraine
M207 for Migraine

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
Novartis To Ape Aimovig's US Market Strategy In The EU As CHMP Gives Market Go-Ahead
Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price
Teva Pushes CGRP Timeline Back To End Of 2018
Teva On Tenterhooks Over Fremanezumab As Celltrion Gets CRLs

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
Biohaven To Apply Catalent's Zydis Technology To Migraine Candidate
Alder Ends Patent Dispute With Teva, Can Take Migraine Candidate Forward
AstraZeneca Divests Zomig To Grunenthal
Eli Lilly Pays Nearly $1bn To Regain Migraine Candidate It Once Sold For $1m

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
Recent events

BIBLIOGRAPHY
Prescription information

LIST OF FIGURES
Figure 1: Trends in prevalent cases of migraine, 2016-25
Figure 2: Pipeline drugs for migraine in the US
Figure 3: Pipeline drugs for migraine, by company
Figure 4: Pipeline drugs for migraine, by drug type
Figure 5: Pipeline drugs for migraine, by classification
Figure 6: Atogepant for Migraine: Phase IIb/III - CGP-MD-01
Figure 7: Emgality for Migraine: Phase III - Chronic Cluster Headache, Phase III - Episodic Cluster Headache
Figure 8: Ubrogepant for Migraine: Phase III - ACHIEVE II
Figure 9: Ubrogepant for Migraine: Phase III - ACHIEVE I
Figure 10: Eptinezumab for Migraine: Phase III - PROMISE 1
Figure 11: Rimegepant for Migraine: Phase III - BHV-3000-301, Phase III - BHV3000-302
Figure 12: Rimegepant for Migraine: Phase III - BHV-3000-301, Phase III - BHV3000-302
Figure 13: Ubrogepant for Migraine: Phase III - ACHIEVE I
Figure 14: Aimovig for Migraine: Phase IIIb - LIBERTY
Figure 15: Eptinezumab for Migraine: Phase III - PROMISE 2
Figure 16: Emgality for Migraine: Phase III - Long Term Migraine
Figure 17: Lasmiditan for Migraine: Phase III - COL MIG-302
Figure 18: Eptinezumab for Migraine: Phase III - PROMISE 2
Figure 19: Fremanezumab for Migraine: Phase III - HALO EM
Figure 20: Fremanezumab for Migraine: Phase III - HALO CM
Figure 21: Emgality for Migraine: Phase III - EVOLVE-1, Phase III - EVOLVE-2, Phase III - REGAIN
Figure 22: M207 for Migraine: Phase II/III - Zotrip
Figure 23: Key upcoming events in migraine
Figure 24: Probability of success in the migraine pipeline
Figure 25: Licensing and asset acquisition deals in migraine
Figure 26: Parent patents in migraine, 2018-28
Figure 27: Parent patents in migraine, 2028-37
Figure 28: Clinical trials in migraine
Figure 29: Top 10 drugs for clinical trials in migraine
Figure 30: Top 10 companies for clinical trials in migraine
Figure 31: Trial locations in migraine
Figure 32: Migraine trials status
Figure 33: Migraine trials sponsors, by phase

LIST OF TABLES
Table 1: Prevalent cases of migraine, 2016-25
Table 2: Prevalence proportions of migraine, 2016-25
Table 3: Marketed drugs for migraine
Table 4: Approvals by country for migraine
Table 5: Pipeline drugs for migraine in the US
Table 6: Fremanezumabor for Migraine
Table 7: Atogepant for Migraine
Table 8: Emgality for Migraine
Table 9: Ubrogepant for Migraine
Table 10: Ubrogepant for Migraine
Table 11: Eptinezumab for Migraine
Table 12: Rimegepant for Migraine
Table 13: Rimegepant for Migraine
Table 14: Ubrogepant for Migraine
Table 15: Aimovig for Migraine
Table 16: Eptinezumab for Migraine
Table 17: Emgality for Migraine
Table 18: Lasmiditan for Migraine
Table 19: Eptinezumab for Migraine
Table 20: Fremanezumab for Migraine
Table 21: Fremanezumab for Migraine
Table 22: Emgality for Migraine
Table 23: M207 for Migraine
Table 24: Historical global sales, by drug, 2013-17
Table 25: Forecasted global sales, by drug, 2018-22

For more information about this report visit https://www.researchandmarkets.com/r/cezp90

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs , Analgesics